• July 7, 2020
  • 0

This April 28, 2009 photo shows Novavax, a Rockville, Maryland, company that in 2005 turned its attention to flu vaccines, is testing cell-based technologies to enable it to produce a flu vaccine in as little as three months, half as long as traditional flu vaccine makers, which use an egg-based process. Shortening the process is key, because flu can mutate rapidly. As concern spread about a swine flu virus outbreak, investors saw opportunity in shares of companies that make or hope to make anti-flu drugs, with Novavax shares leap 80 percent. AFP PHOTO/Paul J. Richards (Photo credit should read PAUL J. RICHARDS/AFP via Getty Images)

Upstate News Headlines

PHP Code Snippets Powered By : XYZScripts.com